ALK and lung carcinoma: The drugs include epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKI) for lung cancers with EGFR‐sensitive mutations,10, 11, 12, 13, 14, 15, 16, 17 osimertinib for those with the EGFR T790M mutation,18 anaplastic lymphoma kinase (ALK) inhibitors for those with ALK mutations, and ROS1 inhibitors with c‐ROS oncogene 1 (ROS‐1) fusion genes.19, 20, 21, 22